FIELD: medicine.
SUBSTANCE: method for producing an agent possessing cytostatic action on human lymphoblasts, wherein chicken blood sampling is preceded by electrical stimulation of chickens' heads at 100-120 V, 3-5 A, for 3-5 seconds; that is followed by sampling and incubating the blood, recovering serum and peptide fraction from the serum at molecular weight 850-1200 Da to be lyophilised and sterilised by exposing in a linear electron accelerator in a dose of 28-32 kGy.
EFFECT: method enables producing an agent, which effectively suppresses malignant cells in acute lymphocytic leukaemia in the patient's body, reduces haematological and immunological toxicity and a risk of severe complications observed in anti-cancer chemotherapy.
3 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR OBTAINING BIOLOGICALLY ACTIVE SUBSTANCE FROM CHICKEN BLOOD FOR ACTIVATION OF PROLIFERATION OF NON-DIFFERENTIATED CELLS OF HUMAN MARROW CELLS | 2012 |
|
RU2508297C1 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF OBTAINING ANTIONCOLOGIC FRACTIONS OF BLOOD SERUM (AF BS) | 2009 |
|
RU2426548C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARING ANTIVIRAL FRACTIONS (ANTIVIRUS-C) | 2012 |
|
RU2526799C2 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN THE PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIAS WITH ANTI-TUMOR PREPARATIONS DAUNORUBICIN AND CYTOSINE-ARABINOSIDE | 2019 |
|
RU2702657C1 |
| BIOTREATMENT BLOOD SERUM, METHODS OF PRODUCTION AND APPLICATION | 2004 |
|
RU2364404C2 |
| APPLICATION OF PROTEIN EXTRACT AS ANTIPROLIFERATIVE AND CYTOTOXIC AGENT | 2017 |
|
RU2671632C1 |
| MEANS OF ANTI-CLONOGENIC ACTIVITY IN RESPECT OF TUMOR HUMAN CELLS | 2016 |
|
RU2648820C2 |
| N,N'((ALKANDIYL)BIS[LABDA-7(9),13,14-TRIENE-4-CARBOXAMIDES] WITH ANTITUMOUR ACTIVITY | 2017 |
|
RU2654201C1 |
| FLUORESCENT METHOD FOR CHEMOTHERAPY EFFICIENCY PREDICTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA BY DETERMINATION OF ADENOSINE TRIPHOSPHATE CONCENTRATIONS IN MITOCHONDRIA | 2016 |
|
RU2642589C2 |
| METHOD FOR INCREASING EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITORS USING THERAPEUTIC COMPOSITION BASED ON INDOLE DERIVATIVES AND PROBIOTIC | 2023 |
|
RU2826495C1 |
